Results 61 to 70 of about 14,668 (165)

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion

open access: yesAsia-Pacific Journal of Oncology Nursing, 2018
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment ...
Tracy King   +7 more
doaj   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

open access: yesHistopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung   +7 more
wiley   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy

open access: yes, 2021
Daratumumab is an integral part of the treatment of multiple myeloma (MM) but its real-world efficacy has only been described in small cohorts. MAMMOTH is the only large multi-center study that reported the outcomes of CD38-refractory MM.
Thorsen, Jonathan   +17 more
core   +1 more source

P28 | ON DEMAND PLERIXAFOR FOR STEM CELL MOBILIZATION WITH G-CSF ONLY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB: A SINGLE CENTER EXPERIENCE

open access: yesHaematologica
Daratumumab is increasingly used as a part of the induction therapy in patients with newly diagnosed multiple myeloma (NDMM) and is associated with deeper responses to treatment.
B. Skopec, L. Cemazar, M. Skerget
doaj   +1 more source

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

open access: yesAsian Journal of Transfusion Science, 2017
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 ...
Mei-Hwa Lin   +4 more
doaj   +1 more source

Multiple Myeloma in a Resource‐Limited Setting: Clinical Presentation, Treatment Patterns, and Outcomes From a 99‐Patient Cohort in Senegal

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background: Therapeutic advances have profoundly improved outcomes in multiple myeloma (MM) in high‐income countries. In sub‐Saharan Africa; however, data remain scarce and access to novel therapies is limited. We aimed to characterize the clinical presentation, treatment strategies, and outcomes of MM patients managed in a resource‐limited ...
Nata Dieng   +7 more
wiley   +1 more source

MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins

open access: yes, 2019
Daratumumab, a therapeutic IgG kappa monoclonal antibody, can cause a false positive interference on electrophoretic assays that are routinely used to monitor patients with monoclonal gammopathies.
Cho, Sun   +2 more
core   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1518-1530, December 2026.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera   +24 more
wiley   +1 more source

First report of daratumumab interference in urine immunofixation electrophoresis confirmed by the HYDRASHIFT 2/4 Daratumumab assay

open access: yes
A case of analytical interference in urine immunofixation electrophoresis (IFE) caused by daratumumab is presented. Daratumumab, an IgG1-kappa monoclonal antibody, is well-known to produce a false IgG-kappa band in serum IFE, but urinary interference has
Hyun-Woo Lee   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy